Navigation Links
Matrixx Initiatives, Inc. Summarizes Ongoing 'Go-Shop' Process and Board Reaffirms Recommendation
Date:1/21/2011

party.  Matrixx remains open to receiving competing proposals and will continue to work with its financial advisor through the balance of the go-shop period (which expires January 22) to continue to solicit and encourage alternative acquisition proposals.  However, Sawaya Segalas has advised the management of the Company that it does not believe any proposal will be submitted as a result of its go-shop efforts.

In view of the current absence of any proposal or indication of interest, and for the reasons provided in the Company's Solicitation/Recommendation Statement on Schedule 14D-9 for the transaction filed with the United States Securities and Exchange Commission ("SEC") on December 22, 2010, as amended, (the "Schedule 14D-9"), the Company's board of directors continues to recommend that the stockholders of Matrixx accept the tender offer and tender their shares of common stock to Wonder pursuant to the tender offer.  

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is an over-the-counter healthcare company that develops and markets Zicam® products. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products in the cough and cold category. The Company markets Zicam brand pharmaceuticals, including Zicam Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc., visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, President and Chief Executive Officer, at 602-385-8888, or Bill Barba, Vice President of Finance & Accounting, at 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.

Notice to Investors

This pr
'/>"/>

SOURCE Matrixx Initiatives, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2010 Financial Results
2. Matrixx Initiatives, Inc. Sets Time for Discussion of Fourth Quarter and Fiscal 2010 Financial Results
3. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 First Quarter Financial Results
4. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 Second Quarter Financial Results
5. Matrixx Initiatives, Inc. and H.I.G. Capital Announce Early Termination of HSR Waiting Period
6. Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21) Per Share
7. Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
10. New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation
11. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of ... clinical results from its Phase IIa clinical trial ... to treat type 1 diabetes. The trial was conducted ... under a U.S. Food and Drug Administration (FDA) ...
(Date:10/22/2014)... Oct. 22, 2014   Surefire Medical , Inc., ... designed to maximize targeted delivery of embolization agents in ... that oncologist John R. Daniels , MD of ... and surgical oncologist Steven C. Katz , MD ... Company,s Scientific Advisory Board (SAB).    "The ...
(Date:10/22/2014)... -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing ... for cancer, is designed for injection into solid tumors ... focus is on melanoma, breast cancer and cancers of ... PV-10 as a therapy for metastatic melanoma, and of ... psoriasis. This summer, the Company signed ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... lead to increased blood pressure, according to a new study. ... blood pressure for young adult women or for teenagers, according ... lightly or moderately, their risk of high blood pressure was ... studies in older adult men and women," said lead researcher ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... who was diagnosed with Ebola while working for NBC News ... can leave the special isolation unit at Nebraska Medical Center in ... the hospital said Tuesday. A blood test confirmed by the ... 33, can head home to Providence, R.I., NBC News ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... a booth at the American Foundation for Suicide Prevention’s ... The AFSP is a not-for-profit organization that hosts hundreds ... proceeds from these events are used to help understand ... education and personal relationships as well. , The ...
(Date:10/20/2014)... 20, 2014 hc1.com today announced ... cloud solution that enables healthcare organizations of all ... healthcare-specific customer relationship management (“CRM”) solution. , Designed ... needs of the healthcare industry, the hc1 Healthcare ... and patients by combining healthcare CRM, HIPAA-compliant collaboration, ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
... , , SAN FRANCISCO, Sept. 23 ... in Elder Care award by the popular content site for senior living, ... This award is given to individuals who exhibit leadership, ideas and drive ... was sited for his work in driving brain fitness to consumers, said ...
... , , , ... agencies, consumer advocacy groups and industry to educate expecting parents about ... for preserving them, three out of every four pregnant women still ... an international meeting on stem cell science and policy found that ...
... , , , , ... Aviva Family and Children,s Services , a non-profit, ... abused and at-risk youth in the greater Los Angeles community, hosted ... Wednesday, September 9, 2009. Los Angeles Mayor Antonio Villaraigosa and ...
... cutting back on birth control to save money, survey finds, ... pregnancy and having fewer children because of the recession, but ... for it, a new survey finds. , "The recession has ... senior research associate at the Guttmacher Institute, which issued its ...
... FRANCISCO, CA SEPTEMBER 23, 2009 Late-breaking data ... 4,000 patients in the U.S., shows that an everolimus-eluting ... of de novo native coronary artery lesions when compared ... loss" may be achieved with drug-eluting stents without sacrificing ...
... are powerful computer-simulation modeling techniques that used increasingly ... such as tumor growth, the immune system, and ... Researchers will gather Dec. 1-3 at the ... on the University of Tennessee, Knoxville (UTK), campus ...
Cached Medicine News:Health News:Leader in Elder Care Award to Posit Science CEO 2Health News:Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education 2Health News:Data Released at an International Stem Cell Meeting Highlights Effectiveness of New Patient Education System Developed to Support Federal and State Guidelines on Cord Blood Education 3Health News:Aviva Family and Children's Services Hosts Rededication Ceremony of the Newly Renovated Wallis Annenberg Center 2Health News:Recession Has Women Rethinking Childbearing 2Health News:Recession Has Women Rethinking Childbearing 3Health News:SPIRIT IV trial shows everolimus stent sets new standard for event-free survival 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... are offered as 1-piece or modular, in ... instruments may be customized with handles of ... insulation and flush ports. Many standard patterns ... may affect delivery times. , Please ...
Medicine Products: